Mechanistic studies have shown that IL-35 reduces the severity of psoriasis in mice by inhibiting proinflammatory cytokines in the skin microenvironment, suppressing the recruitment of MDSCs, and reducing the population of iNOS-expressing MDSCs. This evidence concerns the gene NOS2 and psoriasis.